Skip to main content

AI May Be Useful in Polypharmacy Management

Medically reviewed by Carmen Pope, BPharm. Last updated on April 24, 2024.

By Lori Solomon HealthDay Reporter

WEDNESDAY, April 24, 2024 -- ChatGPT shows promise in polypharmacy management and deprescribing medications among the elderly, according to a study published online April 18 in the Journal of Medical Systems.

Arya Rao, from Harvard Medical School in Boston, and colleagues evaluated ChatGPT performance in polypharmacy management via its binary (yes/no) deprescribing decisions in standardized clinical vignettes.

The researchers found that in yes/no binary deprescribing decisions, ChatGPT universally recommended deprescribing medications regardless of activities of daily living (ADL) status in patients with no overlying cardiovascular disease (CVD) history. Among patients with CVD history, ChatGPT answers varied by technical replicate. The range for total number of medications deprescribed was 2.67 to 3.67 (out of seven) and did not vary with CVD status. However, the number of medications deprescribed increased linearly with severity of ADL impairment. ChatGPT preferentially deprescribed pain medications.

"Our study provides the first use case of ChatGPT as a clinical support tool for medication management," senior author Marc Succi, M.D., from Medically Engineered Solutions in Healthcare Incubator, Innovation in Operations Research Center in Boston, said in a statement. "While caution should be taken to increase accuracy of such models, artificial intelligence-assisted polypharmacy management could help alleviate the increasing burden on general practitioners. Further research with specifically trained artificial intelligence tools may significantly enhance the care of aging patients."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

Read this next

342 Cardiology Clinics Acquired by Private Equity Firms in 2013 to 2023

WEDNESDAY, July 3, 2024 -- From 2013 to 2023, 342 cardiology clinics were acquired by private equity firms, with 94.7 percent of the acquisitions occurring between 2021 and 2023...

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.